Zacks Investment Research on MSN1d
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
Zacks.com on MSN3d
TSVT Up on Acquisition Agreement With BMY for $286 MillionTSVT gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb BMY. Per the terms of ...
Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...
The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...
Fintel on MSN3d
Leerink Partners Downgrades 2seventy bio (TSVT)Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 2seventy bio, Inc. (NASDAQ: TSVT) to Bristol Myers Squibb for $5.0 ...
Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...
In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...
CAMBRIDGE, Mass., February 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming TD Cowen 45th Annual ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback